DoD Multiple Sclerosis, Investigator- Initiated Research Award | W81XWH 20 MSRP IIRA

Opportunity Information: Apply for W81XWH 20 MSRP IIRA

The DoD Multiple Sclerosis (MS) Investigator-Initiated Research Award (IIRA) is a U.S. Department of Defense funding opportunity designed to support ambitious, well-justified research projects that could meaningfully advance the understanding of multiple sclerosis and/or improve patient care. The emphasis is on highly rigorous, high-impact science, meaning proposals are expected to be thoughtfully designed, methodologically sound, and positioned to produce results that matter to the MS field. While the program is open to a wide range of research directions, it is specifically intended to move the needle in MS research rather than fund incremental work with limited potential influence.

A key feature of this award is its broad scope across the research pipeline, with one major boundary: clinical trials are not allowed under this mechanism. Applicants can propose studies at essentially any other phase, such as basic laboratory research, translational work that bridges bench discoveries toward practical applications, mechanistic studies, biomarker development and validation, preclinical model development, or clinically oriented research that does not cross the line into a clinical trial. This flexibility is meant to encourage investigators to pursue well-founded, creative ideas wherever they sit in the discovery-to-care continuum, as long as the work remains outside the formal clinical trial category.

The program also clarifies that strong research ideas can originate from many sources, not just traditional laboratory hypotheses. The rationale for a proposal may be grounded in prior lab discoveries, lessons learned from completed clinical trials, insights from population-based or epidemiological studies, a clinician's direct experience treating people with MS, or even carefully considered anecdotal observations that point to a meaningful and testable scientific question. In practice, this signals that the sponsor values real-world relevance and encourages applicants to connect their proposed aims to tangible needs or gaps in MS knowledge and care.

Another central requirement is that applications must include preliminary and/or published data relevant to MS and the proposed project. In other words, this is not intended to be purely speculative funding; applicants need to show some level of existing evidence that supports feasibility and strengthens the scientific premise. Those data can come from the applicant's own prior work or from the published literature, but they must clearly tie to multiple sclerosis and to the specific direction being proposed. This requirement typically raises expectations around readiness, with proposals needing a credible foundation demonstrating that the team can execute the work and that the underlying idea is supported by real signals rather than conjecture.

From an administrative standpoint, the opportunity is listed as discretionary and supports funding through either grants or cooperative agreements, under the Department of Defense (Department of the Army, U.S. Army Medical Research Acquisition Activity, USAMRAA). It falls under the Science and Technology and other Research and Development activity category and is associated with CFDA number 12.420. Eligibility is described as unrestricted, meaning it is broadly open to many types of applicant organizations, subject to any additional eligibility clarifications that may appear in the full announcement text. The opportunity number is W81XWH 20 MSRP IIRA, it was created on April 24, 2020, and the original closing date was October 1, 2020. The listing indicates an expected number of awards of about seven, while the award ceiling is shown as 0, which usually means the ceiling may not be specified in the summary record and applicants would need to consult the full solicitation for budget limits, cost constraints, and any caps or guidance on allowable funding levels.

Overall, the IIRA is best understood as a competitive DoD mechanism for investigators who already have a solid evidence base and a strong, MS-relevant research plan, and who can articulate why their approach is likely to produce high-value outcomes for the MS research community and, ultimately, for patients. The program invites a wide range of scientifically grounded ideas, but it expects applicants to bring rigor, demonstrated feasibility, and a clear line of sight to meaningful impact, while staying outside the clinical trial space.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Multiple Sclerosis, Investigator- Initiated Research Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Apr 24, 2020.
• Applicants must submit their applications by Oct 01, 2020. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 7 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 20 MSRP IIRA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: